Effectiveness of mRNA-1273 vaccine booster against COVID-19 in immunocompetent adults.

Ana Florea Lina S SyLei QianBradley K AckersonYi LuoJulia E TubertGina S LeeJennifer H KuKatia J BruxvoortCarla A TalaricoSijia QiuYun TianHung Fu Tseng

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Among immunocompetent adults, the mRNA-1273 booster conferred additional protection against SARS-CoV-2 infection and severe COVID-19 disease compared to the 2-dose mRNA-1273 primary series during periods of Delta and Omicron predominance.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
binding protein
randomized controlled trial
early onset